April 2, 2026

Science Chronicle

A Science and Technology Blog

April 2, 2026

Science Chronicle

A Science and Technology Blog

COVID-19

Clinical trialHealthHuman challenge studiesResearch

Are human challenge studies effective? 

Are human studies more challenging than clinical trials, and what are the benefits in a country where the burden of infectious diseases is high?

Read More
Communicable diseaseCoronavirusCOVID-19Public HealthResearchSARS-CoV-2

Novel host-directed molecules blunt SARS-CoV-2, influenza virus

Virus can develop resistance against antivirals, while drugs that target the host cells to prevent virus infection can remain effective even when the virus evolves

Read More
Communicable diseaseCoronavirusPublic HealthSARS-CoV-2Sewage surveillanceTesting

Wastewater study detects a large, silent wave in Bengaluru

The XBB.1.16 Omicron recombinant first detected in India on December 25, 2022 has become the dominant variant in the country.

Read More
Communicable diseaseCoronavirusomicronPublic HealthResearchSARS-CoV-2

Omicron variants evolve strategies to evade T cell immunity

The cellular mechanisms and consequences of enhanced MHC I inhibition by Omicron variants on infection and disease remain to be determined

Read More
COVID-19ResearchSARS-CoV-2

SARS-CoV-2 virus not found in animal samples from Huanan seafood market, says study

The absence of the virus in samples collected from raccoon dogs and the inability of the study to establish the origin of the virus is in complete variance to the conclusions of a team led by evolutionary biologist Michael Worobey

Read More
CoronavirusCOVID-19Genome sequencingResearchSARS-CoV-2

GISAID temporarily lifts ban on authors of Zenodo report on the origin of COVID-19 pandemic

GISAID says it reversed its stand and lifted the temporary access restrictions as a ‘show of goodwill’ and did so after it received a reply from the authors on March 21

Read More
CoronavirusomicronPublic HealthSARS-CoV-2Testing

No cause for alarm: On the Omicron recombinant XBB.1.16 in India

More than three years after the pandemic began, newer variants, an uptick in cases, hospitalisations, and even deaths are being reported from

Read More
COVID-19ResearchSARS-CoV-2World Health Organisation

WHO has not abandoned COVID-19 origin investigation

Two years after the WHO’s visit to China to investigate the origin of COVID-19, the WHO has “abandoned” the second phase of the investigation

Read More
Communicable diseaseCoronavirusCOVID-19omicronPublic HealthSARS-CoV-2

Why India has not witnessed any surge in COVID-19 cases for months

Daily COVID-19 cases in India are low despite the newer Omicron subvariants, recombinants possessing greater immune escape and transmissibility The

Read More
Communicable diseaseCoronavirusCOVID-19omicronPublic HealthSARS-CoV-2

Is Omicron variant XBB.1.5’s superior binding causing higher transmissibility?

XBB.1.5 is the most transmissible variant that has been detected yet, and it has already spread to over 29 countries so far

Read More
Communicable diseaseCoronavirusCOVID-19omicronPublic HealthSARS-CoV-2Vaccines

Sooner or later, India has to develop Omicron-based boosters

Vaccines based on Omicron variants are better than the ones based on the ancestral strain, but the older vaccines are still effective

Read More
COVID-19Genome sequencingPublic HealthSARS-CoV-2

Scaling up the pace of COVID-19 genome sequencing

Three years after strict enforcement of its Zero-COVID strategy, China abandoned it abruptly, leading to a jump in cases each

Read More
COVID-19SARS-CoV-2Vaccines

More vaccine choices: On Bharat Biotech’s intranasal COVID-19 vaccine

Nearly three months after Bharat Biotech’s intranasal COVID-19 vaccine was granted emergency use approval for primary vaccination of adults, the vaccine has now

Read More